Infectious Vaccines Industry Research Report 2025
Description
Summary
According to APO Research, the global Infectious Vaccines market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Infectious Vaccines include Sanofi Pasteur (France), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), MedImmune LLC (U.S.), Emergent Bio Solutions Inc. (U.S.) and CSL Limited (Australia), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Infectious Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infectious Vaccines.
The report will help the Infectious Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Infectious Vaccines market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Infectious Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Infectious Vaccines Segment by Company
Sanofi Pasteur (France)
Johnson and Johnson (U.S.)
Novartis AG (Switzerland)
Merck and Company (U.S.)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc. (U.K.)
MedImmune LLC (U.S.)
Emergent Bio Solutions Inc. (U.S.)
CSL Limited (Australia)
Bavarian Nordic (Denmark)
Infectious Vaccines Segment by Type
Preventive Vaccine
Therapeutic Vaccine
Infectious Vaccines Segment by Application
Adults
Pediatrics
Infectious Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infectious Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Infectious Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Infectious Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Infectious Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Infectious Vaccines market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Infectious Vaccines is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Infectious Vaccines include Sanofi Pasteur (France), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), MedImmune LLC (U.S.), Emergent Bio Solutions Inc. (U.S.) and CSL Limited (Australia), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Infectious Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infectious Vaccines.
The report will help the Infectious Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Infectious Vaccines market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Infectious Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Infectious Vaccines Segment by Company
Sanofi Pasteur (France)
Johnson and Johnson (U.S.)
Novartis AG (Switzerland)
Merck and Company (U.S.)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc. (U.K.)
MedImmune LLC (U.S.)
Emergent Bio Solutions Inc. (U.S.)
CSL Limited (Australia)
Bavarian Nordic (Denmark)
Infectious Vaccines Segment by Type
Preventive Vaccine
Therapeutic Vaccine
Infectious Vaccines Segment by Application
Adults
Pediatrics
Infectious Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infectious Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Infectious Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Infectious Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Infectious Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
120 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Infectious Vaccines Market Size (2020-2031)
- 2.2.2 Global Infectious Vaccines Sales (2020-2031)
- 2.2.3 Global Infectious Vaccines Market Average Price (2020-2031)
- 2.3 Infectious Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 Preventive Vaccine
- 2.3.3 Therapeutic Vaccine
- 2.4 Infectious Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Adults
- 2.4.3 Pediatrics
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Infectious Vaccines Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Infectious Vaccines Sales (k units) of Manufacturers (2020-2025)
- 3.3 Global Infectious Vaccines Revenue of Manufacturers (2020-2025)
- 3.4 Global Infectious Vaccines Average Price by Manufacturers (2020-2025)
- 3.5 Global Infectious Vaccines Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Infectious Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Infectious Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Infectious Vaccines, Established Date
- 3.9 Global Infectious Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Sanofi Pasteur (France)
- 4.1.1 Sanofi Pasteur (France) Company Information
- 4.1.2 Sanofi Pasteur (France) Business Overview
- 4.1.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Sanofi Pasteur (France) Infectious Vaccines Product Portfolio
- 4.1.5 Sanofi Pasteur (France) Recent Developments
- 4.2 Johnson and Johnson (U.S.)
- 4.2.1 Johnson and Johnson (U.S.) Company Information
- 4.2.2 Johnson and Johnson (U.S.) Business Overview
- 4.2.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio
- 4.2.5 Johnson and Johnson (U.S.) Recent Developments
- 4.3 Novartis AG (Switzerland)
- 4.3.1 Novartis AG (Switzerland) Company Information
- 4.3.2 Novartis AG (Switzerland) Business Overview
- 4.3.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 Novartis AG (Switzerland) Infectious Vaccines Product Portfolio
- 4.3.5 Novartis AG (Switzerland) Recent Developments
- 4.4 Merck and Company (U.S.)
- 4.4.1 Merck and Company (U.S.) Company Information
- 4.4.2 Merck and Company (U.S.) Business Overview
- 4.4.3 Merck and Company (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Merck and Company (U.S.) Infectious Vaccines Product Portfolio
- 4.4.5 Merck and Company (U.S.) Recent Developments
- 4.5 Pfizer Inc. (U.S.)
- 4.5.1 Pfizer Inc. (U.S.) Company Information
- 4.5.2 Pfizer Inc. (U.S.) Business Overview
- 4.5.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio
- 4.5.5 Pfizer Inc. (U.S.) Recent Developments
- 4.6 GlaxoSmithKline plc. (U.K.)
- 4.6.1 GlaxoSmithKline plc. (U.K.) Company Information
- 4.6.2 GlaxoSmithKline plc. (U.K.) Business Overview
- 4.6.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio
- 4.6.5 GlaxoSmithKline plc. (U.K.) Recent Developments
- 4.7 MedImmune LLC (U.S.)
- 4.7.1 MedImmune LLC (U.S.) Company Information
- 4.7.2 MedImmune LLC (U.S.) Business Overview
- 4.7.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio
- 4.7.5 MedImmune LLC (U.S.) Recent Developments
- 4.8 Emergent Bio Solutions Inc. (U.S.)
- 4.8.1 Emergent Bio Solutions Inc. (U.S.) Company Information
- 4.8.2 Emergent Bio Solutions Inc. (U.S.) Business Overview
- 4.8.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio
- 4.8.5 Emergent Bio Solutions Inc. (U.S.) Recent Developments
- 4.9 CSL Limited (Australia)
- 4.9.1 CSL Limited (Australia) Company Information
- 4.9.2 CSL Limited (Australia) Business Overview
- 4.9.3 CSL Limited (Australia) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 CSL Limited (Australia) Infectious Vaccines Product Portfolio
- 4.9.5 CSL Limited (Australia) Recent Developments
- 4.10 Bavarian Nordic (Denmark)
- 4.10.1 Bavarian Nordic (Denmark) Company Information
- 4.10.2 Bavarian Nordic (Denmark) Business Overview
- 4.10.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)
- 4.10.4 Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio
- 4.10.5 Bavarian Nordic (Denmark) Recent Developments
- 5 Global Infectious Vaccines Market Scenario by Region
- 5.1 Global Infectious Vaccines Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Infectious Vaccines Sales by Region: 2020-2031
- 5.2.1 Global Infectious Vaccines Sales by Region: 2020-2025
- 5.2.2 Global Infectious Vaccines Sales by Region: 2026-2031
- 5.3 Global Infectious Vaccines Revenue by Region: 2020-2031
- 5.3.1 Global Infectious Vaccines Revenue by Region: 2020-2025
- 5.3.2 Global Infectious Vaccines Revenue by Region: 2026-2031
- 5.4 North America Infectious Vaccines Market Facts & Figures by Country
- 5.4.1 North America Infectious Vaccines Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Infectious Vaccines Sales by Country (2020-2031)
- 5.4.3 North America Infectious Vaccines Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Infectious Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Infectious Vaccines Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Infectious Vaccines Sales by Country (2020-2031)
- 5.5.3 Europe Infectious Vaccines Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Infectious Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Infectious Vaccines Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Infectious Vaccines Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Infectious Vaccines Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Infectious Vaccines Market Facts & Figures by Country
- 5.7.1 South America Infectious Vaccines Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Infectious Vaccines Sales by Country (2020-2031)
- 5.7.3 South America Infectious Vaccines Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Infectious Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Infectious Vaccines Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Infectious Vaccines Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Infectious Vaccines Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global Infectious Vaccines Sales by Type (2020-2031)
- 6.1.1 Global Infectious Vaccines Sales by Type (2020-2031) & (k units)
- 6.1.2 Global Infectious Vaccines Sales Market Share by Type (2020-2031)
- 6.2 Global Infectious Vaccines Revenue by Type (2020-2031)
- 6.2.1 Global Infectious Vaccines Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Infectious Vaccines Revenue Market Share by Type (2020-2031)
- 6.3 Global Infectious Vaccines Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Infectious Vaccines Sales by Application (2020-2031)
- 7.1.1 Global Infectious Vaccines Sales by Application (2020-2031) & (k units)
- 7.1.2 Global Infectious Vaccines Sales Market Share by Application (2020-2031)
- 7.2 Global Infectious Vaccines Revenue by Application (2020-2031)
- 7.2.1 Global Infectious Vaccines Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Infectious Vaccines Revenue Market Share by Application (2020-2031)
- 7.3 Global Infectious Vaccines Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Infectious Vaccines Value Chain Analysis
- 8.1.1 Infectious Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Infectious Vaccines Production Mode & Process
- 8.2 Infectious Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Infectious Vaccines Distributors
- 8.2.3 Infectious Vaccines Customers
- 9 Global Infectious Vaccines Analyzing Market Dynamics
- 9.1 Infectious Vaccines Industry Trends
- 9.2 Infectious Vaccines Industry Drivers
- 9.3 Infectious Vaccines Industry Opportunities and Challenges
- 9.4 Infectious Vaccines Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Infectious Vaccines Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Infectious Vaccines Sales (k units) of Manufacturers (2020-2025)
- Table 7. Global Infectious Vaccines Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Infectious Vaccines Revenue of Manufacturers (2020-2025)
- Table 9. Global Infectious Vaccines Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Infectious Vaccines Average Price (US$/unit) of Manufacturers (2020-2025)
- Table 11. Global Infectious Vaccines Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Infectious Vaccines, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Infectious Vaccines, Product Type & Application
- Table 14. Global Infectious Vaccines Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Infectious Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. Sanofi Pasteur (France) Company Information
- Table 19. Sanofi Pasteur (France) Business Overview
- Table 20. Sanofi Pasteur (France) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 21. Sanofi Pasteur (France) Infectious Vaccines Product Portfolio
- Table 22. Sanofi Pasteur (France) Recent Developments
- Table 23. Johnson and Johnson (U.S.) Company Information
- Table 24. Johnson and Johnson (U.S.) Business Overview
- Table 25. Johnson and Johnson (U.S.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 26. Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio
- Table 27. Johnson and Johnson (U.S.) Recent Developments
- Table 28. Novartis AG (Switzerland) Company Information
- Table 29. Novartis AG (Switzerland) Business Overview
- Table 30. Novartis AG (Switzerland) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 31. Novartis AG (Switzerland) Infectious Vaccines Product Portfolio
- Table 32. Novartis AG (Switzerland) Recent Developments
- Table 33. Merck and Company (U.S.) Company Information
- Table 34. Merck and Company (U.S.) Business Overview
- Table 35. Merck and Company (U.S.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 36. Merck and Company (U.S.) Infectious Vaccines Product Portfolio
- Table 37. Merck and Company (U.S.) Recent Developments
- Table 38. Pfizer Inc. (U.S.) Company Information
- Table 39. Pfizer Inc. (U.S.) Business Overview
- Table 40. Pfizer Inc. (U.S.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 41. Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio
- Table 42. Pfizer Inc. (U.S.) Recent Developments
- Table 43. GlaxoSmithKline plc. (U.K.) Company Information
- Table 44. GlaxoSmithKline plc. (U.K.) Business Overview
- Table 45. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 46. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio
- Table 47. GlaxoSmithKline plc. (U.K.) Recent Developments
- Table 48. MedImmune LLC (U.S.) Company Information
- Table 49. MedImmune LLC (U.S.) Business Overview
- Table 50. MedImmune LLC (U.S.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 51. MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio
- Table 52. MedImmune LLC (U.S.) Recent Developments
- Table 53. Emergent Bio Solutions Inc. (U.S.) Company Information
- Table 54. Emergent Bio Solutions Inc. (U.S.) Business Overview
- Table 55. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 56. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio
- Table 57. Emergent Bio Solutions Inc. (U.S.) Recent Developments
- Table 58. CSL Limited (Australia) Company Information
- Table 59. CSL Limited (Australia) Business Overview
- Table 60. CSL Limited (Australia) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 61. CSL Limited (Australia) Infectious Vaccines Product Portfolio
- Table 62. CSL Limited (Australia) Recent Developments
- Table 63. Bavarian Nordic (Denmark) Company Information
- Table 64. Bavarian Nordic (Denmark) Business Overview
- Table 65. Bavarian Nordic (Denmark) Infectious Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 66. Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio
- Table 67. Bavarian Nordic (Denmark) Recent Developments
- Table 68. Global Infectious Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 69. Global Infectious Vaccines Sales by Region (2020-2025) & (k units)
- Table 70. Global Infectious Vaccines Sales Market Share by Region (2020-2025)
- Table 71. Global Infectious Vaccines Sales by Region (2026-2031) & (k units)
- Table 72. Global Infectious Vaccines Sales Market Share by Region (2026-2031)
- Table 73. Global Infectious Vaccines Revenue by Region (2020-2025) & (US$ Million)
- Table 74. Global Infectious Vaccines Revenue Market Share by Region (2020-2025)
- Table 75. Global Infectious Vaccines Revenue by Region (2026-2031) & (US$ Million)
- Table 76. Global Infectious Vaccines Revenue Market Share by Region (2026-2031)
- Table 77. North America Infectious Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 78. North America Infectious Vaccines Sales by Country (2020-2025) & (k units)
- Table 79. North America Infectious Vaccines Sales by Country (2026-2031) & (k units)
- Table 80. North America Infectious Vaccines Revenue by Country (2020-2025) & (US$ Million)
- Table 81. North America Infectious Vaccines Revenue by Country (2026-2031) & (US$ Million)
- Table 82. Europe Infectious Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 83. Europe Infectious Vaccines Sales by Country (2020-2025) & (k units)
- Table 84. Europe Infectious Vaccines Sales by Country (2026-2031) & (k units)
- Table 85. Europe Infectious Vaccines Revenue by Country (2020-2025) & (US$ Million)
- Table 86. Europe Infectious Vaccines Revenue by Country (2026-2031) & (US$ Million)
- Table 87. Asia Pacific Infectious Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 88. Asia Pacific Infectious Vaccines Sales by Country (2020-2025) & (k units)
- Table 89. Asia Pacific Infectious Vaccines Sales by Country (2026-2031) & (k units)
- Table 90. Asia Pacific Infectious Vaccines Revenue by Country (2020-2025) & (US$ Million)
- Table 91. Asia Pacific Infectious Vaccines Revenue by Country (2026-2031) & (US$ Million)
- Table 92. South America Infectious Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 93. South America Infectious Vaccines Sales by Country (2020-2025) & (k units)
- Table 94. South America Infectious Vaccines Sales by Country (2026-2031) & (k units)
- Table 95. South America Infectious Vaccines Revenue by Country (2020-2025) & (US$ Million)
- Table 96. South America Infectious Vaccines Revenue by Country (2026-2031) & (US$ Million)
- Table 97. Middle East and Africa Infectious Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 98. Middle East and Africa Infectious Vaccines Sales by Country (2020-2025) & (k units)
- Table 99. Middle East and Africa Infectious Vaccines Sales by Country (2026-2031) & (k units)
- Table 100. Middle East and Africa Infectious Vaccines Revenue by Country (2020-2025) & (US$ Million)
- Table 101. Middle East and Africa Infectious Vaccines Revenue by Country (2026-2031) & (US$ Million)
- Table 102. Global Infectious Vaccines Sales by Type (2020-2025) & (k units)
- Table 103. Global Infectious Vaccines Sales by Type (2026-2031) & (k units)
- Table 104. Global Infectious Vaccines Sales Market Share by Type (2020-2025)
- Table 105. Global Infectious Vaccines Sales Market Share by Type (2026-2031)
- Table 106. Global Infectious Vaccines Revenue by Type (2020-2025) & (US$ Million)
- Table 107. Global Infectious Vaccines Revenue by Type (2026-2031) & (US$ Million)
- Table 108. Global Infectious Vaccines Revenue Market Share by Type (2020-2025)
- Table 109. Global Infectious Vaccines Revenue Market Share by Type (2026-2031)
- Table 110. Global Infectious Vaccines Price by Type (2020-2025) & (US$/unit)
- Table 111. Global Infectious Vaccines Price by Type (2026-2031) & (US$/unit)
- Table 112. Global Infectious Vaccines Sales by Application (2020-2025) & (k units)
- Table 113. Global Infectious Vaccines Sales by Application (2026-2031) & (k units)
- Table 114. Global Infectious Vaccines Sales Market Share by Application (2020-2025)
- Table 115. Global Infectious Vaccines Sales Market Share by Application (2026-2031)
- Table 116. Global Infectious Vaccines Revenue by Application (2020-2025) & (US$ Million)
- Table 117. Global Infectious Vaccines Revenue by Application (2026-2031) & (US$ Million)
- Table 118. Global Infectious Vaccines Revenue Market Share by Application (2020-2025)
- Table 119. Global Infectious Vaccines Revenue Market Share by Application (2026-2031)
- Table 120. Global Infectious Vaccines Price by Application (2020-2025) & (US$/unit)
- Table 121. Global Infectious Vaccines Price by Application (2026-2031) & (US$/unit)
- Table 122. Key Raw Materials
- Table 123. Raw Materials Key Suppliers
- Table 124. Infectious Vaccines Distributors List
- Table 125. Infectious Vaccines Customers List
- Table 126. Infectious Vaccines Industry Trends
- Table 127. Infectious Vaccines Industry Drivers
- Table 128. Infectious Vaccines Industry Restraints
- Table 129. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Infectious Vaccines Product Image
- Figure 5. Global Infectious Vaccines Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Infectious Vaccines Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Infectious Vaccines Sales (2020-2031) & (k units)
- Figure 8. Global Infectious Vaccines Average Price (US$/unit) & (2020-2031)
- Figure 9. Preventive Vaccine Product Image
- Figure 10. Therapeutic Vaccine Product Image
- Figure 11. Adults Product Image
- Figure 12. Pediatrics Product Image
- Figure 13. Global Infectious Vaccines Revenue Share by Manufacturers in 2024
- Figure 14. Global Manufacturers of Infectious Vaccines, Manufacturing Sites & Headquarters
- Figure 15. Global Top 5 and 10 Infectious Vaccines Players Market Share by Revenue in 2024
- Figure 16. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 17. Global Infectious Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 18. Global Infectious Vaccines Sales by Region in 2024
- Figure 19. Global Infectious Vaccines Revenue by Region in 2024
- Figure 20. North America Infectious Vaccines Market Size by Country in 2024
- Figure 21. North America Infectious Vaccines Sales Market Share by Country (2020-2031)
- Figure 22. North America Infectious Vaccines Revenue Market Share by Country (2020-2031)
- Figure 23. United States Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 24. Canada Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 25. Europe Infectious Vaccines Market Size by Country in 2024
- Figure 26. Europe Infectious Vaccines Sales Market Share by Country (2020-2031)
- Figure 27. Europe Infectious Vaccines Revenue Market Share by Country (2020-2031)
- Figure 28. Germany Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 29. France Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 30. U.K. Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 31. Italy Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 32. Netherlands Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 33. Nordic Countries Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 34. Asia Pacific Infectious Vaccines Market Size by Country in 2024
- Figure 35. Asia Pacific Infectious Vaccines Sales Market Share by Country (2020-2031)
- Figure 36. Asia Pacific Infectious Vaccines Revenue Market Share by Country (2020-2031)
- Figure 37. China Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 38. Japan Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 39. South Korea Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 40. India Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 41. Australia Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 42. China Taiwan Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 43. Southeast Asia Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 44. Southeast Asia Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. South America Infectious Vaccines Market Size by Country in 2024
- Figure 46. South America Infectious Vaccines Sales Market Share by Country (2020-2031)
- Figure 47. South America Infectious Vaccines Revenue Market Share by Country (2020-2031)
- Figure 48. Mexico Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 49. Brazil Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 50. Argentina Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 51. Colombia Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 52. Middle East and Africa Infectious Vaccines Market Size by Country in 2024
- Figure 53. Middle East and Africa Infectious Vaccines Sales Market Share by Country (2020-2031)
- Figure 54. Middle East and Africa Infectious Vaccines Revenue Market Share by Country (2020-2031)
- Figure 55. Turkey Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 56. Saudi Arabia Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 57. UAE Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 58. Global Infectious Vaccines Sales Market Share by Type (2020-2031)
- Figure 59. Global Infectious Vaccines Revenue Market Share by Type (2020-2031)
- Figure 60. Global Infectious Vaccines Price (US$/unit) by Type (2020-2031)
- Figure 61. Global Infectious Vaccines Sales Market Share by Application (2020-2031)
- Figure 62. Global Infectious Vaccines Revenue Market Share by Application (2020-2031)
- Figure 63. Global Infectious Vaccines Price (US$/unit) by Application (2020-2031)
- Figure 64. Infectious Vaccines Value Chain
- Figure 65. Infectious Vaccines Production Mode & Process
- Figure 66. Direct Comparison with Distribution Share
- Figure 67. Distributors Profiles
- Figure 68. Infectious Vaccines Industry Opportunities and Challenges
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
